Brief: Shanghai Junshi Biosciences Receives FDA Approval Of Investigational New Drug Application For Phase II/III Clinical Study Of JS207
16/10/2025 15:48
Oct 16 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS: FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE II/III CLINICAL STUDY OF JS207 Further company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab